Does the media refer more to ABOS or CTMX?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.48 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RGNX or ABOS?

In the previous week, REGENXBIO had 8 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 10 mentions for REGENXBIO and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.00 beat REGENXBIO's score of -0.40 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ABOS or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A

Is ABOS or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -136.27% -81.64% Tectonic Therapeutic N/A -35.26% -33.59%

Does the media favor ABOS or TECX?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Acumen Pharmaceuticals. Tectonic Therapeutic's average media sentiment score of 1.11 beat Acumen Pharmaceuticals' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ABOS or BBOT?

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A

Is ABOS or BBOT more profitable?

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -136.27% -81.64% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

Does the media refer more to ABOS or BBOT?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. BridgeBio Oncology Therapeutics' average media sentiment score of 0.22 beat Acumen Pharmaceuticals' score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Oncology Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Acumen Pharmaceuticals (ABOS) Competitors

$3.08 -0.08 (-2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$3.12 +0.04 (+1.17%)

As of 04:43 PM Eastern

Compare

ABOS vs. FDMT, CTMX, RGNX, TECX, and BBOT

Should you buy Acumen Pharmaceuticals stock or one of its competitors? Acumen Pharmaceuticals's main competitors and comparable companies include 4D Molecular Therapeutics (FDMT), CytomX Therapeutics (CTMX), REGENXBIO (RGNX), Tectonic Therapeutic (TECX), and BridgeBio Oncology Therapeutics (BBOT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Acumen Pharmaceuticals compare to 4D Molecular Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Acumen Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market.

Acumen Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

In the previous week, 4D Molecular Therapeutics had 15 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 2 mentions for Acumen Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 0.62 beat Acumen Pharmaceuticals' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Acumen Pharmaceuticals has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
4D Molecular Therapeutics	$92.01M	9.24	-$140.11M	-$2.63	N/A

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 159.74%. 4D Molecular Therapeutics has a consensus price target of $29.63, indicating a potential upside of 92.50%. Given Acumen Pharmaceuticals' higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

4D Molecular Therapeutics beats Acumen Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

In the previous week, CytomX Therapeutics had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.48 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acumen Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

CytomX Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 159.74%. CytomX Therapeutics has a consensus price target of $11.90, indicating a potential upside of 261.70%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Acumen Pharmaceuticals has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

Summary

CytomX Therapeutics beats Acumen Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

REGENXBIO has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

REGENXBIO currently has a consensus price target of $23.73, indicating a potential upside of 194.38%. Acumen Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 159.74%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, REGENXBIO had 8 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 10 mentions for REGENXBIO and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.00 beat REGENXBIO's score of -0.40 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acumen Pharmaceuticals has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.12	-$193.88M	-$3.79	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Acumen Pharmaceuticals' return on equity of -136.27% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Summary

REGENXBIO beats Acumen Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Tectonic Therapeutic?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tectonic Therapeutic's return on equity of -35.26% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Acumen Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 159.74%. Tectonic Therapeutic has a consensus target price of $77.80, suggesting a potential upside of 113.33%. Given Acumen Pharmaceuticals' higher possible upside, research analysts clearly believe Acumen Pharmaceuticals is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Acumen Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, meaning that its share price is 228% more volatile than the broader market.

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Acumen Pharmaceuticals. Tectonic Therapeutic's average media sentiment score of 1.11 beat Acumen Pharmaceuticals' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Acumen Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. BridgeBio Oncology Therapeutics' average media sentiment score of 0.22 beat Acumen Pharmaceuticals' score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acumen Pharmaceuticals currently has a consensus target price of $8.00, indicating a potential upside of 159.74%. BridgeBio Oncology Therapeutics has a consensus target price of $24.40, indicating a potential upside of 166.96%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Acumen Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

Summary

BridgeBio Oncology Therapeutics beats Acumen Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$222.75M	$3.99B	$7.29B	$12.70B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-1.89	11.75	271.38	24.10
Price / Sales	N/A	1,394.70	638.44	90.36
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.66	17.26	11.18	6.40
Net Income	-$121.33M	-$22.72M	$3.46B	$348.28M
7 Day Performance	15.79%	2.89%	1.99%	0.91%
1 Month Performance	44.60%	9.74%	7.32%	5.10%
1 Year Performance	101.31%	54.81%	24.76%	16.16%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	1.5863 of 5 stars	$3.08 -2.5%	$8.00 +159.7%	+106.5%	$222.75M	N/A	N/A	20
FDMT 4D Molecular Therapeutics	3.071 of 5 stars	$14.51 -0.3%	$29.63 +104.1%	+123.3%	$753.19M	$92.01M	N/A	120
CTMX CytomX Therapeutics	2.484 of 5 stars	$3.41 -1.3%	$11.90 +249.5%	+54.7%	$739.77M	$76.20M	N/A	170	Analyst Downgrade
RGNX REGENXBIO	3.6527 of 5 stars	$11.05 -2.5%	$23.73 +114.7%	+19.0%	$729.68M	$170.44M	N/A	370	News Coverage Gap Down Trading Halted
TECX Tectonic Therapeutic	3.1932 of 5 stars	$36.25 +7.1%	$77.80 +114.7%	+43.7%	$721.24M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. FDMT, CTMX, RGNX, TECX, and BBOT

How does Acumen Pharmaceuticals compare to 4D Molecular Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to REGENXBIO?

Summary

How does Acumen Pharmaceuticals compare to Tectonic Therapeutic?

Summary

How does Acumen Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. FDMT, CTMX, RGNX, TECX, and BBOT

How does Acumen Pharmaceuticals compare to 4D Molecular Therapeutics?

Which has more risk & volatility, ABOS or FDMT?

Is ABOS or FDMT more profitable?

Does the media refer more to ABOS or FDMT?

Do insiders and institutionals believe in ABOS or FDMT?

Which has better earnings and valuation, ABOS or FDMT?

Do analysts prefer ABOS or FDMT?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Does the media refer more to ABOS or CTMX?

Is ABOS or CTMX more profitable?

Which has higher earnings and valuation, ABOS or CTMX?

Do analysts recommend ABOS or CTMX?

Do institutionals and insiders believe in ABOS or CTMX?

Which has more volatility & risk, ABOS or CTMX?

Summary

How does Acumen Pharmaceuticals compare to REGENXBIO?

Which has more risk & volatility, RGNX or ABOS?

Do analysts recommend RGNX or ABOS?

Do insiders & institutionals believe in RGNX or ABOS?

Does the media favor RGNX or ABOS?

Which has higher valuation & earnings, RGNX or ABOS?

Is RGNX or ABOS more profitable?

Summary

How does Acumen Pharmaceuticals compare to Tectonic Therapeutic?

Do institutionals & insiders hold more shares of ABOS or TECX?

Is ABOS or TECX more profitable?

Do analysts recommend ABOS or TECX?

Which has preferable earnings and valuation, ABOS or TECX?

Which has more risk & volatility, ABOS or TECX?

Does the media favor ABOS or TECX?

Summary

How does Acumen Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Does the media refer more to ABOS or BBOT?

Do analysts prefer ABOS or BBOT?

Which has more risk & volatility, ABOS or BBOT?

Do insiders and institutionals hold more shares of ABOS or BBOT?

Is ABOS or BBOT more profitable?

Which has higher valuation and earnings, ABOS or BBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools